Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuTec Pharma Ltd.

Division of Novartis AG
www.neutecpharma.com

Latest From NeuTec Pharma Ltd.

Deep-Pocketed Big Pharma Meets Spec Pharma's Challenge

In early 2006, we noted in this space that in-licensing on the part of specialty pharmaceutical start-ups was rising relative to Big Pharma's in-licensing rate, with specialty pharmas even out-competing Big Pharma in some specific cases for rights to promising clinical programs. Since then, however, Big Pharma's unprecedented late-stage spending spree has far outpaced spec pharma's licensing, particularly in clinical stage deals.
BioPharmaceutical Strategy

The A-List: 2006's Trend-Shaping Series A Financings

2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.
BioPharmaceutical Medical Device

Novartis' M&A Machine

M&A is competitive, and not all subjects are willing ones. Senior executives at Novartis, Big Pharma's number two acquirer, describe their system for identifying acquisition targets, understanding their priorities and walking away if prices get out of hand.
BioPharmaceutical Consumer

Auctions: Getting the Best Value for Your Asset

Given the competition for increasingly rare pipeline-fillers, most of today's licensing and M&A deals are auctions--a term used loosely to describe any situation where there's more than one bidder for an asset. But auctions come in various flavors; knowing which one to use requires a deep understanding of your asset, and its value to others.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • NeuTec Pharma PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • James Burnie, PhD, CEO
    Ruth Matthews, PhD, R&D Dir.
  • Contact Info
  • NeuTec Pharma Ltd.
    Phone: (44) 61 276 8827
    2nd Floor Clinical Sciences Bldg.
    Oxford Rd.
    Manchester,
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register